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OncOlOgy & HematOlOgy Review maintenance/continuous treatment, as well as how to choose the best option of therapy for an optimized disease control, are also discussed.
Induction Regimens Classic Combinations
Melphalan was the first active alkylating agent used for the treatment of MM patients, and MP was the standard of care for over 30 years, although it yielded only PR in 40-60 % of patients, with <5 % of CRs, and a PFS of approximately 18 months and OS of 2-3 years. 5 With the introduction of novel agents, new combinations based on alkylating agents have been tested and compared with MP.
Bendamustine has been incorporated into the treatment armamentarium of MM, as the rebirth of an old drug. It has structural similarities to both alkylating agents and purine analogs and it is currently approved for the treatment of newly diagnosed MM patients not candidates to HDT-ASCT who cannot receive thalidomide or bortezomib due to peripheral neuropathy (PN). The rationale for the approval was a randomized trial in which bendamustine plus prednisone (BP) was compared with MP. The ORR was 75 % for the BP arm and 70 % for MP. However, the CR rate was 32 % with BP compared with 13 % with MP (p=0.007), with a benefit in terms of time-to-treatment failure (14 months for BP compared with 10 months for MP; p=0.02), with no difference in overall survival. 6 The toxicity profile was similar and hematologic toxicity, nausea, and vomiting were the most-frequent adverse events (AEs) reported with BP.
Thalidomide-based Regimens
Six randomized trials compared the combination of MP plus thalidomide (MPT) with the standard MP. [7] [8] [9] [10] [11] [12] The PR rate was 42-76 % versus 28-48 % with MPT and MP, respectively, and PFS was 14-28 versus 10-19 months.
Although in three out of the six trials, the PFS advantage observed with MPT also translated into a significant OS advantage (37-52 versus 28-32 months), this was not confirmed in the three other trials. Despite this, results obtained with MPT suggest that the three-drug combination is far superior to the standard MP and these data supported the use of MPT as one of the standard of care for elderly MM patients (see Table 1 ).
A meta-analysis of pooled data of 1,682 patients from the six MPT trials previously mentioned showed that the addition of thalidomide to MP as a frontline regimen in elderly MM patients is associated with a significant prophylaxis is required when using MPT. 
Lenalidomide-based Regimens
The combination of melphalan, prednisone, and lenalidomide followed by maintenance with lenalidomide (MPR-R) has been compared with fixed 18 The Len/Dex regimen was associated with a higher ORR than Len/dex (79 % versus 68 %; p=0.008) but the 1-year OS was superior for low-dose dexamethasone, without differences at 3 years (see Table 1 ).
However, in patients over 65 years old a survival benefit with low-dose regimen was observed, even when using a landmark analysis to eliminate the 5 % early deaths seen in the first 4 months of treatment. At least in part, this difference was due to the greater toxicity of the high-dose dexamethasone (the incidence of grade 3 or 4 VTE events was 26 % versus 12 %; infections, 16 % versus 9 %; fatigue, 15 % versus 9 %). This trial has been the basis for the current use of low-dose dexamethasone in almost all patients with MM.
In the most remarkable recent study involving 1,623 patients not eligible for transplantation (IFM07-01, MM020) the combination of Len/dex administered until disease progression or intolerance was compared with MPT administered for 72 weeks or Len/dex administered for the same fixed period of time. 19 The trial showed a significant benefit for continuous Len/dex treatment compared with MPT or Len/dex for 18 Len/dex will likely become a frequently used protocol but especially will become a new backbone to which novel agents will be added. 22 (see Table 1 ). However, the addition of Table 1 ).
Bortezomib-based Regimens
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Carfilzomib-based Combinations
The second-generation proteasome inhibitors are also emerging as new 
Monoclonal Antibodies
Elotuzumab, an anti-signaling lymphocytic activation molecule F7 (SLAMF7) monoclonal antibody, has proved to be safe and effective in combination with Len/dex in relapsed and refractory MM patients, and a randomized trial comparing Len/dex ± elotuzumab in newly diagnosed elderly MM patients is currently underway. and most during the first infusions. 29 A randomized trial evaluating VMP ± daratumumab is already planned and it will start in the near future.
Regimens Based on Proteasome Inhibitors and Immunoregulatory Drugs
The Spanish myeloma group compared VTP, in the same reduced-intensity bortezomib schedule previously presented, with VMP as induction therapy, in order to try to decrease toxicity and maintain efficacy. After six induction cycles, the grade 3 or 4 PN was 9 % and the ORR was 81 %, including 28 % of CR rate; the continuous treatment thereafter with VT or VP as maintenance therapy resulted in a PFS of 32 months and a 5-year OS of 53 %. 24 The Italian group, in the trial previously described (VMPT versus VMP), the four-drug combination VMPT followed by VT maintenance resulted in an incidence of grade 3 or 4 PN of 8 %. The ORR after induction therapy was 89 %, with 38 % of CR rates, and 3-year PFS and OS of 56 % versus 89 % (see Table 1) . 30 Pilot studies have tested the efficacy of the combination of bortezomib, lenalidomide, and dexamethasone in elderly newly diagnosed MM patients, but modifying the different drug doses to optimize the combination (RVD light including bortezomib once per week, lenalidomide at reduced doses, and low or very-low dexamethasone). Preliminary results in 30 patients showed after four induction cycles an ORR of 90 %, including a 17 % CR rate, with an acceptable toxicity profile. 31 Carfilzomib has been combined with lenalidomide plus low-dose dex (CRd) in a pilot phase I/II trial in newly diagnosed MM patients, including young and elderly patients. 32 Results of a subanalysis of 23 elderly MM patients showed impressive efficacy (100 % of ORR, with stringent CR in 65 % of patients), and an acceptable toxicity profile (13 % of grade 1-2 PN). All patients remained free of progression and alive at the median follow up of 1 year (see Table 1 ). 33 These results support a phase III study of CRd versus Rd in all age groups.
Ixazomib plus lenalidomide and low-dose dexamethasone is being also compared with lenalidomide plus low-dose dexamethasone alone in a randomized trial in non-transplant candidates MM patients supported by the positive results showed with ixazomib in weekly schedule plus Len/ dex (90 % of patients had achieved at least PR, including a VGPR rate of 59 % and a CR rate of 22 %) with good tolerability (see Table 1 ). 34 This triplet was followed by ixazomib as maintenance and it will be discussed on the maintenance section.
How to Improve and Sustain the Efficacy of Treatment? The Role of Continuous Therapy
Despite the improvement in treatment responses and survival associated with the introduction of novel antimyeloma treatments, all patients with MM eventually relapse due to the persistence of residual disease. Recent data indicate that long-term treatment either as maintenance or continuous therapy can be an approach to sustain the remission by keeping the tumor under control. In elderly patients, the efficacy of long-term treatment should be balanced with tolerability and convenience of use.
Thalidomide Maintenance
Three studies compared a thalidomide maintenance arm following MP (MPT-T) versus no maintenance. 10, 11, 35 All these studies reported an improvement in TTP and PFS (or event-free survival) but only the DutchBelgian study 10 reported a significant improvement in OS for MPT-T compared with MP alone (40 versus 31 months; p=0.05). However, the incidence of PN of grade ≥2 during maintenance was 54 %. The MRC Myeloma IX trial of attenuated CTD versus MP, also contained a thalidomide maintenance randomization. 36 Thalidomide maintenance therapy was associated with an improvement in PFS (p=0.01) but OS was not significantly prolonged.
Thalidomide maintenance was not well tolerated and patients remained on treatment for a median of only 7 months. Altogether, these studies indicate that thalidomide maintenance does not represent a treatment of choice due to its poor tolerability.
Bortezomib Maintenance
The Spanish study discussed above, which compared VMP and VTP as induction therapy, included a maintenance phase with either VT or VP for up to 3 years. Maintenance therapy upgraded the overall CR rate from 24 % to 42 %, being slightly higher for VT compared with VP (46 % versus 39 %; p=NS). After median follow-up of 46 months, PFS was 39 months in the VT group compared with 32 months in the VP arm (p=0.1) with a trend to better OS for VT (69 % versus 50 % at 5 years). 37 Both regimens were well tolerated with no serious hematologic toxicities, although VT maintenance was associated with a higher incidence of PN (9 % versus 3 %). The previously mentioned Italian trial that compared VMPT as induction therapy with VMP also included a maintenance phase with VT in the former arm. CR rates after maintenance upgraded up to 38 % in the VMPT-VT group. The median PFS was significantly longer with VMPT-VT than with VMP (37 months versus 27 months; HR 0.58; p<0.0001), resulting in a significant benefit to OS (61 % versus 51 % at 5 years, HR 0.70; p=0.01). 30 Maintenance with VT was well tolerated: grade 3 or grade 4 hematologic AEs were reported by 3 % of patients, and grade 3 or grade 4 PN were found in 5 % of patients. In the UPFRONT study previously mentioned presented in which three different induction regimens (VD versus VTD versus VMP) were compared, all patients received maintenance therapy with bortezomib alone given in a weekly schedule. This approach only slightly improved the quality of response. 23 
Carfilzomib Maintenance
The above trial presented evaluating carfilzomib, cyclophosphamide, and dexamethasone included maintenance with carfilzomib until disease progression. Results are preliminary but carfilzomib single agent as maintenance was able to increase the ORR from 47 % to 56 % and the CR rate from 23 % up to 32 %. Tolerability was manageable, resulting in less than 5 % of discontinuations. 28 
Ixazomib Maintenance
Ixazomib single agent as maintenance followed the induction with the triplet ixazomib plus Len/dex. Though preliminary results, 10 (48 %) patients improved their response during maintenance (two VGPR to nCR, five VGPR to CR, one VGPR to sCR, and two CR to sCR) and also contributed to the duration of the response, showing a trend to longer PFS. 38 A phase III trial of ixazomib plus lenalidomide-dexamethasone versus placebo plus lenalidomide-dexamethasone in patients with previously untreated MM is currently enrolling (TOURMALINE-MM2).
Lenalidomide Maintenance
The thrombocytopenia, neutropenia, VTE, and fatigue (1-3 %). 16 The 3-year risk for second primary tumors was 7 %, confined to acute leukemias or myelodysplastic syndromes, and the interaction between melphalan and lenalidomide can increase the leukemogenic risk. However, the benefit of treatment appears to outweigh the risk for second primary tumors. 
Individualized Treatment Strategies for Non-transplant Candidate Patients
The different novel treatment combinations offer physicians the possibility to tailor treatment approaches based on the individual patient profile and patient's preference. For instance, in patients who have a history of VTE, VMP may be a preferred treatment choice as it is less thrombogenic. However, appropriate anticoagulant prophylaxis has been shown to reduce VTE complications to approximately 3 % in patients treated with lenalidomide-or thalidomide-containing regimens. 40 In patients with pre-existing neuropathy, MPR, Rd, or BP would be a good choice for upfront treatment since they are not associated with neurotoxicity. In patients with renal failure, thalidomide, bortezomib, and bendamustine can be administered at the full approved dose; lenalidomide requires adjustments of the starting dose based on the creatinine clearance.
Elderly MM patients are a heterogeneous group of patients and many of them, regardless of the biologic age, are physically frail, with multiple comorbid conditions (e.g. diabetes, renal impairment, cardiovascular disease) and physical disabilities (e.g. arthritis, dementia). In addition, we have learnt that tolerability is a major concern in this patient's population.
Therefore, all physicians treating elderly MM patients should consider these points before prescribing treatment: a) To assess the biologic age, comorbidities, frailty, and disability; b) To evaluate the degree of functional impairment in order to select the most appropriate drug regimen, adapting dose if required (see Table 2 ); 41, 42 and c) To optimize the supportive care treatment with bisphosphonates, growth factors, anticoagulants, antibiotics, antivirals, and pain control. In addition to dose reductions, cyclophoshamide should be considered as an alternative to melphalan and prednisone may be better tolerated than dexamethasone in frail elderly patients.
Conclusions and Future Perspectives
The availability of new combination regimens has increased the treatment options for elderly patients ineligible for HDT-ASCT resulting into a significant prolongation of the OS. MPT, VMP, Len/dex, and BP represent new standards of care for transplant-ineligible patients. Other combinations such as RVD, as well as Len/dex plus the novel proteasomeinhibitor carfilzomib or ixazomib are also in clinical development.
Monoclonal antibodies in the future will be incorporated to the induction regimen and they will be evaluated as part of the maintenance plan.
Maintenance treatment with novel agents is emerging as a new strategy to sustain disease control and delay disease progression. Individualized treatment for elderly patients is mandatory through a correct geriatric evaluation before the start of therapy. n 
